Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented preclinical data at the AACR 2022 highlighting the efficacy of combining its Ac-225-HER3 antibody radiation conjugate with Gilead's magrolimab, an anti-CD47 antibody. The study demonstrated significant tumor control improvement in HER3-positive models compared to magrolimab alone. The data suggests enhanced phagocytosis and upregulation of calreticulin, indicating stronger anti-tumor responses. Actinium aims to further develop this combination for treating solid tumors and blood cancers, leveraging its technology and strategic collaborations.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) and AVEO Oncology (NASDAQ: AVEO) announced a research collaboration to develop a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, utilizing Actinium's AWE technology platform with Ac-225. This partnership aims to enhance targeted cell killing in hard-to-treat cancers. AVEO will leverage its expertise in high-affinity antibodies to advance the development of this novel radiotherapy. Both companies are excited about the potential impact on patient outcomes and the expansion of their oncology portfolios.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has partnered with EpicentRx, Inc. to explore the combination of Actimab-A, a targeted radiotherapy, with RRx-001, an immunotherapy targeting the CD47-SIRPα axis, for treating acute myeloid leukemia (AML). This collaboration aims to enhance the immune system's ability to detect and destroy cancer cells. Actinium recently presented data indicating positive outcomes from combining targeted radiotherapy with anti-CD47 antibody treatments. Actinium's ongoing clinical pipeline includes several therapies aimed at improving cancer treatment precision.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented encouraging results from the Phase 1 Actimab-A and CLAG-M trial at the 63rd ASH Meeting. The trial showed a complete remission rate (CR/CRp) across all dose cohorts and an 80% overall response rate in patients with less than 4 prior therapies. Notably, the MRD negativity rate was 72%, significantly higher than the 39% seen with CLAG-M alone. The study identified 0.75uCi/kg of Actimab-A as the recommended Phase 2 dose with no 30-day mortality reported. These findings bolster plans for future development in AML treatment.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced positive results from the Phase 1 trial of Actimab-A combined with venetoclax for treating relapsed or refractory acute myeloid leukemia (AML). Presented at the 63rd ASH Annual Meeting, the trial showed a 67% overall response rate, including two remissions in patients with a TP53 mutation. Notably, there has been no early mortality in the study. The trial aims to finalize the dosing for the Phase 2 study, addressing the significant unmet need for patients who do not respond to existing therapies.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced positive results from the fully enrolled Phase 3 SIERRA trial of Iomab-B at the 63rd ASH Annual Meeting. Iomab-B, an antibody radiation conjugate targeting CD45, aims to facilitate bone marrow transplants for patients aged 55+ with relapsed or refractory acute myeloid leukemia (r/r AML). The trial demonstrated a significant difference, with 100% engraftment rates in the Iomab-B arm compared to only 21% in the conventional care arm. The company anticipates topline data in Q3 2022, potentially leading to a BLA filing with the FDA.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation in the Targeted Radiopharmaceuticals Summit from December 7-9, 2021. The company will feature expert speakers from its R&D and Clinical Development teams in two significant panel discussions on December 9. Topics include the development of Alpha Emitting Therapies and optimizing therapeutic strategies. Actinium focuses on targeted radiotherapies, particularly its lead product, I-131 apamistamab (Iomab-B), which targets patients with acute myeloid leukemia. The firm emphasizes its proprietary AWE technology in advancing its clinical pipeline.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced significant findings at the 36th Annual Meeting of the Society for Immunotherapy for Cancer. Their data on an anti-HER2 antibody radiation conjugate (ARC) in combination with a CD47 blocking antibody showed promising results in solid tumor models. Key highlights include increased phagocytosis by 2-fold and enhanced tumor control. The findings support ongoing research into this combination therapy, aiming to improve patient outcomes. The poster is available on Actinium's website, showcasing advancements in targeted radiotherapies.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented data on Actimab-A, an antibody radiation conjugate, at the 36th Annual Meeting of the Society for Immunotherapy for Cancer from November 12-14, 2021. The findings demonstrated that Actimab-A, when combined with a CD47 blocking antibody, significantly increased survival in AML tumor models and enhanced cell surface calreticulin levels, potentially improving the immune response. This combination indicates promising therapeutic potential for treating acute myeloid leukemia (AML).